Dogwood Therapeutics(DWTX)
ALPHARETTA, GABiotechnology
Focus: Dogwood Therapeutics is a public biotech company focused on small-molecule development in neurology, currently advancing a Phase 2 candidate for chemotherapy-induced neuropathic pain. With 501–1000 employees and a market cap implied by NASDAQ listing (DWTX), the company operates at mid-cap biotech scale.
Profile data last refreshed 21h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Employees
501-1000
Open Jobs
0
About Dogwood Therapeutics
AI assessmentNot HiringNo open roles listed right now. Follow Dogwood Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Dogwood Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Data completeness
4/9 — Basic
Company HealthSolid
Pipeline
Early-stage
1 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
PHASE_2
Clinical Trials (1)
NCT06848348Efficacy and Safety Study of Halneuron in the Treatment of Chemotherapy-Induced Neuropathic Pain
Phase 2Help build intelligence for Dogwood Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.